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Abstract
Background: The use of Hartmann’s procedure in the old and frail and/or in patients with fecal incontinence is
increasing, even though some data have reported high postoperative rates of pelvic abscesses. Abdominoperineal
excision with intersphincteric dissection has been proposed as a better alternative and is performed increasingly
both nationally and internationally. However, no studies have been performed to support this. The aim of this study is to
randomize patients between Hartmann’s procedure and abdominoperineal excision with intersphincteric dissection and
compare post-operative surgical morbidity and quality of life. The hypothesis is that intersphincteric abdominoperineal
excision provides less pelvic and perineal morbidity.
Methods/design: In this multicentre randomized controlled study, Hartmann’s procedure will be compared with
intersphincteric abdominoperineal excision in patients with rectal cancer unsuitable for an anterior resection. The
patients are operated in different ways around the ano-rectum, otherwise the same procedure is performed with
total mesorectal excision and all will receive a colostomy. The one-month postoperative control will focus on
post-operative surgical complications, especially the perineal-pelvic, reoperations and other interventions. After
one year, late complications such as pain in the perineal or pelvic area or disorders such as secretion or bleeding
from the anorectal stump will be recorded and a follow-up of quality of life performed. Histological and
oncological data will also be recorded, the latter up to 5 years post-operatively.
Discussion: The HAPIrect trial is the first randomized controlled trial comparing standard low Hartmann’s
procedure with intersphincteric abdominoperineal excision in patients with rectal cancer with the aim of
categorizing the post-operative surgical morbidity.
Trial registration: ClinicalTrials.gov Identifier: NCT01995396. Date of registration November 25, 2013.
Background
In patients with rectal cancer, low anterior resection
(LAR) with total mesorectal excision (TME) is standard
procedure [1]. Patients with rectal cancer are often elderly,
many have comorbidities and some have a weak sphincter
function with difficulties in keeping their stools. Anasto-
motic leakage after LAR is considered of multifactorial
origin. Patients with co-morbidities like cardiovascular
and/or pulmonary diseases (with impaired tissue perfusion
and oxygenation) and therefore high ASA-class may be
more prone to leakage. To reduce the risk of a life-
threatening complication such as anastomotic leakage
with fecal peritonitis, and/or to avoid crippling problems
with fecal incontinence after LAR, a Hartmann’s proced-
ure (HP) is sometimes performed [2]. In recent years, the
proportion of rectal cancer patients, undergoing HP has
increased from 10 to 15 % [3] and even more (30 %) in
rectal cancer patients with metastases [4]. Many believe
that HP is a safe operation, easy and quick to perform and
associated with a low major complication rate and mortal-
ity [5–7]. It has been argued that the advantage of leaving
a short ano-rectal stump, is that the patient experiences
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less problems with secretion and bleeding from the
remaining rectum.
In recent years, there has arisen a debate in which
some argue that the complication rate after HP is high,
especially after leaving a very short rectal stump. A high
frequency of pelvic abscesses, 12–33 %, are reported
following a low HP, where the rectum is stapled off just
above the pelvic floor [8–10]. Reasons for the high rate
of pelvic complications in previous studies might be the
selection of unfit patients with reduced vascular blood
supply, even more pronounced after the low HP. The
surgical technique, especially the transection of the rec-
tum at the pelvic floor is probably also of importance.
The broadest possible transverse stapler that fits into the
pelvis in order to avoid tension in the stapler line
(mostly 45 and 60 mm), has been proposed [7].
The alternative to a low HP would be to perform an
abdominoperineal excision (APE) to avoid leaving a
suture line on the rectum stump left in the pelvis, in
order to reduce the risk of a suture line insufficiency
which migth lead to a pelvic abscess. However, the
problem with APE is that perineal necrosis and wound
infections are common, with perineal wound problems
ranging between 15 and 38 %, the latter after neoadju-
vant radiotherapy [11]. This can probably be reduced to
a large extent, especially after radiotherapy,by removing
the anus with an intersphincteric dissection (ID), ie the
muscular pelvic floor and external sphincter are left in
situ. This means that one can seal the perineum with
healthy muscle tissue, which improves healing as
opposed to the traditional APE with sutures in the fatty
tissue. Moreover, fat tissue suturing is often problematic
as APE creates a large wound that is difficult to close,
leaving blood/fluid cavities, which further increase the
risk of infection. Intersphincteric proctectomy has been
used for inflammatory bowel diseases such as Crohn’s
disease and ulcerative colitis, and offers significantly less
perineal defects than the traditional APE [12–14].
Whether an intersphincteric APE is better than HP in
rectal cancer patients with regard to postoperative
complications is unclear, although there are theoretical
advantages. There are no published papers on the
subject or on intersphincteric APE practised in rectal
cancer patients, only a few abstracts that suggests low
post-operative surgical complication rates after inter-
sphincteric APE.
With regard to HP, there are no randomized studies or
systematic reviews, only small case studies that have
been analyzed retrospectively. In the few published stud-
ies of HP, the patients are often old with comorbidities,
since HP is frequently the selected method for old or
infirm patients. In the prevailing studies on HP, it has
been compared with APE and/or anterior resection and
data are not conclusive. The studies are heterogeneous
and the study populations are not balanced. The patients
that are preferably selected for HP, are very frail with
high risk of post-operative complications and prolonged
hospital stay. Therefore it is especially important to
perform an operation that reduces the post-operative
surgical complications as much as possible. A multicentre
randomized study to identify the appropriate operative
method for these old and frail patients with rectal cancer
is warranted.
In this multicentre randomized study, we intend to
compare the post-operative events after two surgical
methods that can be used for rectal cancer in patients
who are elderly, have other comorbidities or infirmities,
and/or poor sphincter function, and thereby are not suited
for a colo-anal/rectal anastomosis. The intention is to
randomize patients between HP and APE with ID to
investigate which method gives the lowest post-operative
morbidity, and is associated with the best quality of life.
The hypothesis is that an intersphincteric APE is superior
to HP with regard to post-operative morbidity and quality
of life.
Methods/design
The HAPIrect trial is a multicentre, randomized study
comparing Hartmann’s procedure with intersphincteric
abdominoperineal excision in patients with rectal cancer.
Patients with resectable rectal cancer are random-
ized to either (A) a traditional Hartmann’s procedure
or (B) abdominoperineal excision with ID of the ano-
rectal stump. The patients are operated differently
around the ano-rectum, otherwise the same procedure
is performed.
Definitions: Rectal cancer: tumour border within
15 cm from the anal verge. Pelvic abscess: 1) pus-
secretion via the anus and/or a clinical/endoscopic
defect in the rectal suture line. 2) Computer tomog-
raphy verified pelvic abscess.
Primary endpoint
 The primary objective of this trial is to observe the
rate of local surgical complications (as graded by the
Clavien-Dindo scale) within 30 days.
Secondary endpoints:
 Frequency of intra-operative rectal perforations.
 Duration of operation.
 Amount of blood loss.
 Re-operation and re-intervention (eg, percutaneous
and transanal drainage) rate.
 Post-operative length of hospital stay.
 Re-admission frequency.
 Histology with TNM-status and resection margins.
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 Local recurrence and metachronous distant
metastasis rate.
 Survival after 3 and 5 years.
 Quality of life 1 year after surgery.
 Late local complications from the perineum or ano-
rectal area within 1 year follow-up.
Study population
All patients at the participating clinics that fulfil the
inclusion and exclusion criteria described below shall be
assessed whether they can be included in the study. To
further illustrate patient selection, data on all patients
with rectal cancer who are continously registered in the
Swedish ColoRectal Cancer Registry (SCRCR), will be
reviewed and evaluated retrospectively to find out how
many were not included in the study (exclusions or
missing) and possibly reasons for this.
Inclusion criteria:
 Age 18 years or older.
 Proven rectal cancer by biopsy.
 Tumour 5 cm or higher from the anal verge, and a
Hartmann’s procedure is assessed to be locally
curative.
 Both operations should be performable.
 Impaired functional capacity and/or severe co-
morbidity where an anterior resection and anasto-
mosis is deemed very risky.
 Impaired sphincter function and where an anterior
resection is deemed not suitable.
 Surgery may be palliative but shall be assessed to be
locally radical.
Exclusion criteria:
 Rectal cancer below 5 cm from the anal verge.




Primary investigation prior to randomization
Medical history: co-morbidities, smoking, dementia,
sphincter function, WHO performance scale.
Survey: digital rectal examination, rigid rectoscopy,
colonic examination, CT scan of lungs and abdomen
(or ultrasound liver and plain chest X-ray if certain
renal insufficiency) and MRI of the rectum.
Consecutive patients examined for rectal cancer as
above, will be evaluated for their suitability for inclusion
in the studie. After all inclusion and exclusion criteria
have been verified, the patient will be informed about
the trial at the outpatient clinic and informed consent
will be obtained.
Protocols
Inclusion protocol and collected data
To be completed at inclusion. Patients that are eligible
for inclusion - but are not included - are recorded, stat-
ing the reason for exclusion. This is to seek control of
selection bias. If the patients themselves choose not to
participitate the reason for this may not be asked.
At the outpatient clinic, the patient is also asked to
participate in a study concerning quality of life. This
study is managed separately from the Department of
Surgery, Sahlgrenska University Hospital/Östra, Sweden
(NCT01477229).
Registration protocol and collected data
Data on medical history, the medical work-up, labora-
tory data and operative data that are not collected in the
SCRCR peroperative protocol, are recorded.
The following variables are recorded: age, sex, weight,
height, ASA grade, WHO performance, dementia, symp-
toms, fecal incontinence, smoking, tumour location and
height, TNM stage according to MRI, tethering of the
tumour according to rectal exploration, presence of metas-
tas, laboratory tests (albumin, CRP, WBC, Hb), previous
radiotherapy, neo-adjuvant oncological treatment. Type of
surgery, tumour location visavi peritoneal reflection,
ligation of inferior mesenteric artery or not, skill level of
the surgeon, width of bowel stapler (mm), make of surgical
stapler, operation time, bleeding, associated peri-operative
complications, ano-rectal stump divided or not in inter-
sphincteric APE.
Participating clinics and surgeons
During the last decades, rectal cancer surgery in Sweden
has been concentrated to not more than one hospital in
most counties with a catchment area around 250 000 or
more. All hospitals in Sweden that perform surgery on
patients with rectal cancer have the opportunity to
participate in the study. According to the decision of the
Regional Ethics Council in Uppsala (No: 2013/297),
applications from the following research principals were
accepted:
County Region of Västmanland, County Region of
Värmland, County Region of Gävleborg, County Region of
Uppsala, County Region of Västra Götaland, County
Region of Östergötland, County Region of Sörmland,
County Region of Västernorrland, Region Scania, County
Region of Örebro and Stockholm County Region.
The trial will be conducted at six university hopitals
and 12 county hospitals.
Experience in total mesorectal excision (TME) is
demanded for surgeons taking part in the trial. If the
operation is performed laparoscopically assisted, the
surgeons should be experienced in this technique.
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Randomization
The patients will be fully informed preoperatively orally
and in writing and will have to sign an informed consent.
We will explain pros and cons about the two types of
operations and that we don’t know which one is the most
appropriate and that we will make the randomisation
during the operation. The patients are fully aware and
have accepted this procedure if they are included in the
study. This procedure was chosen to avoid bias in the
selection of patients as regard the type of surgery. If you
randomize before surgey then some surgeons could chose
to not to include some patients because they want to
perform one of the two types of surgery that they believe
is easier, better or goes faster. This is the point, we don’t
know which of the two types of surgery that is most
appropriate for the patient because there exists no data or
comparative studies. That’s why it is so important to ran-
domisze during surgery to avoid this selection. Our Ethics
committee in Uppsala have accepted this procedure.
The randomization procedure is performed in the op-
eration theatre when the TME has been performed, the
distal bowel tube has been clamped and a washout of
the anorectum performed.
Randomization is performed per center by a central
automated internet randomization module through the
website ”www.norrlandskirurgi.se” and stratified for each
centre. The website includes all necessary information
and protocols.
Surgery
The operation, common to both surgical procedures
An experienced TME surgeon participates. The patient
is stoma-marked pre-operatively by a trained nurse.
Antibiotic prophylaxis, thrombosis prophylaxis, continu-
ous thoracic epidural and laxatives are administered ac-
cording to local practice. The patient is positioned with
lowered leg supports.
The abdominal dissection is performed with a high or
low ligation of the inferior mesenteric artery,dissection
along the rectal mesentery, performing a total mesorec-
tum excision down to the pelvic floor. A bowel clamp is
applied below the tumour and the rectum is rinsed
according to local practice. A suitable stapler is placed
distally below the bowel clamp. The stapler is closed with-
out fireing. The stapler is left in place. Now randomization
is performed using the trial website. According to the
results of the randomization (HP or APE with ID), the
procedure is continued.
Arm 1
Resection of the rectum with distal closure and colostomy
(Hartmann)
The stapler is fired and the tumour-bearing bowel speci-
men is removed. The distal colon is brought out as an
ostomy on the abdominal wall via the rectus muscle.
One or two passive drainages are applied in the
pelvis. The abdominal fascia is closed with a suture
quota of > 4:1.
Arm2
Abdominoperineal resection with intersphincteric dissection
(APE + ID)
Depending on personal experience, the stapler is fired
without cutting the intestine, or the staple is fired and
the bowel cut and the tumour-bearing bowel specimen
removed. Thereafter an intersphincteric dissection of the
ano-rectal stump is performed. In the first option ID is
performed with the entire tumour-bearing bowel intact,
in the latter ID is carried out after the bowel specimen is
removed. The surgery continues with the patient prefer-
ably in a lithotomy position. Again, the anus is carefully
washed and the anus is sealed tightly with two purse-
string sutures. The skin in the inner edge of the external
sphincter is incised, and the dissection is carried out in
the intersphincteric plane up along the external sphinc-
ter, levator muscles and the puborectalis sling and into
the pelvis. The specimen is either removed through the
perineum or the abdomen, depending on whether you
have stapled off the rectum distally or not, see above.
The puborectalis, the levator and the external sphincter
and the perineal skin, are sutured from the inside out.
The distal colon is brought out as an ostomy on the
abdominal wall through the rectus muscle. One or two
passive drainages are applied in the pelvis. The abdom-
inal fascia is closed with a suture quota of > 4:1.
Laparoscopic/robotic assisted surgery
Surgeons experienced in laparoscopic TME participates.
Surgery is performed as in the open technique with
TME dissection down to the levator. The rectum is
closed distal to the tumour with a laparoscopic Satinský
or an angled 45 mm stapler. Alternatively, the abdomen
is opened with a Pfannenstiel incision above the pubic
bone and the same clamping procedure as in open sur-
gery is performed. After a rectal washout, the patient is
randomized via the trial website, see above.
ARM 1
If randomized to HA: transect the bowel with the laparo-
scopic stapler below the Satinský, or transect with cutting
stapler below the non-cutting stapler - or alternatively
transect through a Pfannelstiel incision and cut the bowel
with knife above the stapler - and remove the specimen
through an abdominal incision.
ARM 2
If randomized to APE with ID, the bowel can be trans-
sected with the laparoscopic stapler below the clamp, or
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transected with a cutting stapler below the non-cutting
stapler –or alternatively transected through a Pfannelstiel
incision and the specimen removed via the abdominal
incision. ID is then performed as described above in the
ARM 2 open procedure, with the patient in a lithotomy
position. The anorectal specimen is taken out through the
perineal wound.
Follow-up and collected data
The study intends to map the post-operative course.
Follow-up examinations are performed 1 month after
discharge and, if necessary, continuously until the heal-
ing is complete. An additional follow-up is performed
after 12 months with symptom score and quality of life
evaluation. All patients are monitored annually for an-
other 4 years according to the SCRCR protocol.
Follow-up protocol - 30 days
All surgical complications and interventions in the post-
operative course are recorded. At the outpatient clinic 4
weeks after surgery, the patient is re-examined and the 30-
day follow up protocol is completed. Specific complica-
tions are registered such as abdominal wound infection,
perineal wound infection, pelvic abscess, pus-secretion
through the anus, proctitis (patients will be examined with
proctoscopy), fistula, stomal complications, bowel obstruc-
tion, urinary catheter at discharge, cardio-vascular and
other infectious complications. All measures taken due to
surgical complications are registered, including small surgi-
cal or other interventions such as radiological drainage or
drainage transanally. Antibiotic therapy during the hospital
stay, length of stay and re-admissions will be recorded.
Follow-up protocol - 1 year
Late local complications and possible problems with
infection or pain in the perineal or pelvic area or disor-
ders such as secretion or bleeding from the anorectum,
are recorded 1 year after surgery (proctoscopy). Other
data are registered in the SCRCR protocol. At this time,
the patient’s perceived quality of life is investigated using
a separate protocol to be completed by the patient.
After the 1-year follow-up, patients are followed ac-
cording to the SCRCR protocol with annual controls
registering local recurrences, metastases and death.
Sample size considerations and statistics
The literature describes a surgical complication rate of ap-
proximately 35 % after a HP. Most of these complications
are pelvic abscesses whereas after an APE the most fre-
quent complication is a perineal infection. By performing
an intersphincteric dissection, we believe that the perineal
complication rate will be significantly lowered. We assume
that the surgical complication rate can be reduced to 20 %
with an intersphincteric APE. With a type I error of 0.05
(α) and a power of 0.8 (1 - β (0,2)), 140 patients in each
group are needed. With a drop-out estimate of 20 %, the
required sample size is 170 patients in each group. A
research fellow will monitor the data of all included
patients together with the consultants responsible for the
study. A SPSS database will be used containing all
collected parameters. Data analysis will be performed
according to intention-to-treat protocol analysis, an
additional per-protocol analysis will also be performed.
The primary endo-point measure will be evaluated using
chi-squared test. Continuous variables will be compared
with a T-test or Mann-Whitney U where appropriate.
Differences with a P-value <0.05 will be considered
statistically significant. All the statistical analysis will be
conducted by using SPSS version 22 software (SPSS, Inc.,
Chicago, IL, USA).
Discussion
The HAPIrect trial is the first randomized controlled
trial comparing standard low Hartmann’s procedure with
intersphincteric abdominoperineal excision for rectal
cancer. Patients with rectal cancer are increasingly old
and many have other diseases and some have a weak
sphincter function with fecal incontinence. HP has been
increasingly used in the old and frail to reduce the risk
of a life-threatening complication such as an anasto-
motic leakage with fecal peritonitis, and/or to avoid
crippling problems with fecal incontinence after an
anterior resection. To leave a short ano-rectal stump has
been considered to cause less problems with secretion
and bleeding from the remaining rectum. Especially in
patients with metastases there has been an increase in
performing a HP with the intention of avoiding severe
post-operative surgical complications so that post-operative
chemotherapy can be started as soon as possible [4]. Dur-
ing the last decade, there has been an ongoing discussion
whether HP is a safe operation or not and high frequencies
of pelvic abscesses have been reported (8). In the literature,
only small observational studies that have been analyzed
retrospectively can be found. Some authors found very high
rates of pelvic abcsesses, especially after a low HP in up to
33 % of cases [10] compared with only 3 % in another
paper [7]. There have been suggestions that an intesphinc-
teric abdominoperineal excision is a safer procedure. No
data on the use of intersphinteric excision in rectal cancer
have been published but at least in two European centres
efforts have been made to start a randomized trial but due
to different reasons they have not been able to proceed.
The advantage of intersphincteric APE would theoret-
ically be that you avoid leaving a suture line on the
rectum that can leak and cause a pelvic abscess. By
removing the ano-rectal stump with an intersphinc-
teric dissection, the perineo-pelvic defect is small and
can be closed primarily by the levator muscles,thus
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favouring the healing. A disadvantage is the prolonged
duration of surgery and the risk of perforation of the
ano-rectal stump. A multicentre randomized study is
necessary in order to provide evidence to support the
theoretical advantages for intersphincteric abdominoperi-
neal excision. The primary intention is to compare post-
operative surgical morbidity between HP and APE with
intersphincteric dissection. As secondary outcomes, the
study will focus on re-operation and re-intervention, post-
operative length of hospital stay, re-admission frequency,
histological parameters, local recurrence, survival, late
local complications and quality of life. The hypothesis is
that intersphincteric APE provides less pelvic and perineal
morbidity.
Trial status
The trial is open for recruitment from February 2015.
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